Parkinson's disease beyond 20 years

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 8, 2015, Pages 849-855

  Cilia, Roberto ^a   Cereda, Emanuele ^b   Klersy, Catherine ^b   Canesi, Margherita ^a   Zecchinelli, Anna L ^a   Mariani, Claudio B ^a   Tesei, Silvana ^a   Sacilotto, Giorgio ^a   Meucci, Nicoletta ^a   Zini, Michela ^a   Ruffmann, Claudio ^a   Isaias, Ioannis U ^a   Goldwurm, Stefano ^a   Pezzoli, Gianni ^c  

^a PARKINSON INSTITUTE   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABNORMAL POSTURE; ADULT; ARTICLE; COMORBIDITY; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE DURATION; DYSPHAGIA; FEMALE; FOLLOW UP; FRACTURE; HUMAN; IMMOBILITY; INSTITUTIONALIZATION; LABOR ONSET; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEX DIFFERENCE; AGE; ONSET AGE; PROPORTIONAL HAZARDS MODEL; TIME;

AGE FACTORS; AGE OF ONSET; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS;

EID: 84938542429     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308786     Document Type: Article

References (40)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-66.
2. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44.
3. Merola A, Zibetti M, Angrisano S, et al. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 2011;134:2074-84.
4. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007;69:1701-11.
5. Kempster PA, O'Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010;133:1755-62.
6. Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012;8:435-42.
7. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-63.
8. Post B, Merkus MP, de Haan RJ, et al. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007;22:1839-51.
9. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007;64:1242-6.
10. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-57.
11. Kempster PA, Williams DR, Selikhova M, et al. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007;130:2123-8.
12. Dubois B, Pillon B, Sternic N, et al. Age-induced cognitive disturbances in Parkinson's disease. Neurology 1990;40:38-41.
13. Alves G, Wentzel-Larsen T, Aarsland D, et al. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005;65:1436-41.
14. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
15. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-34.
16. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-53.
17. th edn. Washington DC: American Psychiatric Association, 2000.
18. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996;46:1470.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
20. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology 2010;75:1270-6.
21. Reid WG, Hely MA, Morris JG, et al. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 2011;82:1033-7.
22. Hely MA, Morris JG, Traficante R, et al. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-7.
23. Schrag A, Dodel R, Spottke A, et al. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007;22:938-45.
24. Durso R, Isaac K, Perry L, et al. Age influences magnitude but not duration of response to levodopa. J Neurol Neurosurg Psychiatry 1993;56:65-8.
25. Gomez Arevalo G, Jorge R, Garcia S, et al. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Mov Disord 1997;12:277-84.
26. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-698.
27. de la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011;69:803-10.
28. Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009;72(Suppl 7):S32-8.
29. Gould RL, Arroyo B, Brown RG, et al. Brain mechanisms of successful compensation during learning in Alzheimer disease. Neurology 2006;67:1011-17.
30. Inzelberg R, Schecthman E, Paleacu D, et al. Onset and progression of disease in familial and sporadic Parkinson's disease. Am J Med Genet A 2004;124:255-8.
31. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74.
32. Fall PA, Saleh A, Fredrickson M, et al. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18:1312-16.
33. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in Bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 2006;77:468-73.
34. Pouwels S, Bazelier MT, de Boer A, et al. Five-year fracture risk estimation in patients with Parkinson's disease. Bone 2013;56:266-70.
35. Diem-Zangerl A, Seppi K, Wenning GK, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009;24:819-25.
36. Melton LJ III, Leibson CL, Achenbach SJ, et al. Fracture risk after the diagnosis of Parkinson's disease: influence of concomitant dementia. Mov Disord 2006;2:1361-7.
37. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82:1112-18.
38. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84:1258-64.
39. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 2010;25:149-56.
40. Antonini A, Vitale C, Barone P, et al. The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Relat Disord 2012;18:775-80.